<DOC>
	<DOCNO>NCT00780780</DOCNO>
	<brief_summary>Diabetics retinopathy remain major threat sight work age population develop world . Furthermore , increase major cause blindness part world , especially develop country . Diabetic macular edema ( DME ) manifestation diabetic retinopathy produce loss central vision . The triamcinolone intravitreal injection ( 1-4mg ) indicate treatment diabetic macular edema consider important treatment since improves visual acuity patient resolution edema . Nepafenac non-steroidal anti-inflammatory drug ( NSAID ) , usually sell prescription eye drop ( 0.1 % solution ) . Nepafenac manufacture Alcon Nevanac . It approve FDA well ANVISA . Pre-clinical study suggest medication show efficacy treat ocular posterior segment inflammation . The purpose study evaluate efficacy intravitreal triamcinolone associate nepafenac eye drop treatment diabetic macular edema .</brief_summary>
	<brief_title>Efficacy Study Triamcinolone Associated With Nepafenac Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>We plan enroll 40 patient prospective randomized clinical trial . Eligible patient randomize two group . All patient Early Treatment Diabetic Retinopathy Study ( ETDRS ) vision measure OCT ( OCT Stratus - Zeiss ) eye follow visit : Baseline , Week 4 , 8 , 12 , 20 25 . OCT measurement include total macular volume , central foveal thickness , average macular thickness . The patient evaluate 25 week ( 7 visit ) . Parameters clinical evaluation : visual acuity , IOP , biomicroscopy , fundus examination dilate pupil OCT. Group A : 20 patient receive intravitreal triamcinolone injection Group B : 20 patient receive intravitreal triamcinolone injection associate nepafenac eye drop ( 1 gtt , tid ) 6 month .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>18 year age least Diagnosis diabetes mellitus ( type 1 type 2. one following consider sufficient evidence diabetes present : current regular use insulin treatment diabetes current regular use oral hypoglycemic agent treatment diabetes diabetes define american Diabetes Association ( ADA ) symptom diabetes ( polyuria , polydipsia , unexplained weight loss ) eigthhour fast plasma glucose &gt; 126 mg/dl Diabetic macular edema clinically observable associate diabetic retinopathy : prior treat treatment one three session focal laser grid DME , interval session must least 30 day recent laser least 3 month prior Baseline , prior medical therapy diabetic macular edema , investigator opinion patient would benefit macular laser treatment , patient refuse laser treatment BCVA score 34 letter ( 20/320 ETDRS ) e 68 letter ( 20/40 ETDRS ) study eye measure ETDRS method qualification/baseline visit Retinal thickness &gt; 250 um OCT Uncontrolled systemic disease Initiation medical therapy diabetes change oral hypoglycemic agent insulin therapy within 4 month prior qualification visit Renal failure require hemodialysis peritoneal dialysis within 6 month prior qualification visit Any ocular condition study eye opinion investigator would prevent 15 letter improvement visual acuity ( e.g . severe macular ischemia ) Presence branch retinal vein occlusion , central retinal vein occlusion , uveitis , pseudophakic cystoid edema condition study eye could contribute macular edema Presence epiretinal membrane study eye History IOP elevation response steroid treatment either eye History glaucoma optic nerve head change consistent glaucoma damage , and/or glaucomatous visual field loss study eye Ocular hypertension study eye require 1 antiglaucoma medication maintain IOP &lt; 22mmHg qualification visit Presence anterior chamber intraocular lens study eye Active optic disc retinal neovascularization study eye qualification visit Active history choroidal neovascularization study eye Presence rubeosis iris study eye qualification visit Any active ocular infection ( i.e . bacterial , viral , parasitic fungal ) qualification History herpetic infection study eye adnexa Presence active inactive toxoplasmosis either eye qualification Presence visible scleral thin ectasia study eye Media opacity study eye qualification Intraocular surgery , include cataract surgery , and/or laser type study eye within 90 day prior qualification . History central serous chorioretinopathy either eye History par plana vitrectomy study eye History use intravitreal steroid study eye within 3 month prior qualification Periocular depot steroid study eye 3 month prior qualification Use systemic steroid within 1 month prior qualification anticipate use time study Use inhibitor carbonic anhydrase within 1 month prior qualification anticipate use time study Use immunosuppressant , immunomodulators , antimetabolites and/or alkylating agent 6 month prior qualification anticipate use time study BCVA &lt; 34 letter ( 20/200 snellen equivalent ) nonstudy eye use ETDRS qualification Known allergy hypersensitivity study medication component Known allergy contraindication use fluorescein povidone iodine Contraindication pupil dilation either eye Female patient pregnant , nursing , plan pregnancy , childbearing potential use reliable mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>triamcinolone</keyword>
	<keyword>nepafenac</keyword>
	<keyword>DME</keyword>
	<keyword>edema macular</keyword>
</DOC>